Clinical trial / 2016
Five weeks of resveratrol supplementation did not affect GLP-1 secretion, gastric emptying, or glycemic control in type 2 diabetes.
In a randomized, double-blind crossover trial, 14 patients with diet-controlled type 2 diabetes received resveratrol (500 mg twice daily) or placebo for two 5-week periods separated by a 5-week washout. Fasting and postprandial blood glucose, plasma total GLP-1, and gastric emptying were similar at each assessment, and changes from weeks 0 to 5 did not differ between resveratrol and placebo. Changes in HbA1c, daily energy intake, and body weight after 5 weeks also showed no significant differences between treatments.
- Study type
- Double-blind, randomized, crossover trial
- Who was studied
- 14 patients with diet-controlled type 2 diabetes
- What was measured
- GLP-1 secretion, gastric emptying, blood glucose, HbA1c, body weight, and daily energy intake
THE PAPER
Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial.
Thazhath SS, Wu T, Bound MJ, Checklin HL, Standfield S, Jones KL, Horowitz M, Rayner CK. Am J Clin Nutr, 2016.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.